



coordinated care™

Amondys 45 (casimersen)

WA.PHAR.110 Amondys 45 (casimersen)

Effective Date: 07/01/2020

Background:

Amondys 45 (casimersen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Code | Description |
|------------|-------------|
| | |

*National Drug Codes:

| National Drug Code | Description |
|--------------------|--|
| 60923-227-02 | AMONDYS 45 (CASIMERSEN) INJECTION: 100 MG/2 ML IN A SINGLE-DOSE VIAL (3) |

*Please note that the NDCs listed may not be an all-inclusive list

History

| Date | Action and Summary of Changes |
|------------|--|
| 03/08/2021 | <ul style="list-style-type: none"> New Policy Created |